SPOTLIGHT: Glaxo wraps up Reliant buy

GlaxoSmithKline says it's completed its $1.65 billion buyout of U.S.-based heart drug specialist Reliant Pharmaceuticals; the Federal Trade Commission ended the mandatory antitrust waiting period early. Release

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.